Cargando…

TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma

TIGIT is a receptor on human natural killer (NK) cells. Here, we report that TIGIT does not spontaneously induce inhibition of NK cells in glioblastoma (GBM), but rather acts as a decoy-like receptor, by usurping binding partners and regulating expression of NK activating ligands and receptors. Our...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lupo, Kyle B., Torregrosa-Allen, Sandra, Elzey, Bennett D., Utturkar, Sagar, Lanman, Nadia A., Cohen-Gadol, Aaron A., Slivova, Veronika, McIntosh, MacKenzie, Pollok, Karen E., Matosevic, Sandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694670/ http://dx.doi.org/10.1016/j.isci.2023.108353

Ejemplares similares

TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation
por: Dao, Tram N., et al.
Publicado: (2020)

Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors
por: Chambers, Andrea M, et al.
Publicado: (2022)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Adenosinergic Signaling Alters Natural Killer Cell Functional Responses
por: Chambers, Andrea M., et al.
Publicado: (2018)

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
por: Meng, Fanqiao, et al.
Publicado: (2020)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
por: Lupo, Kyle B., et al.
Publicado: (2019)

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma
por: Lupo, Kyle B., et al.
Publicado: (2020)

RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin–ferroptosis axis
por: Li, Zhili, et al.
Publicado: (2023)

The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56(bright) NK cells
por: Ziegler, Annerose E., et al.
Publicado: (2023)

TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
por: Yu, Lihua, et al.
Publicado: (2021)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies
por: Hasan, Md Faqrul, et al.
Publicado: (2023)

TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4(+) T cells
por: Holder, Kayla A, et al.
Publicado: (2021)

PD1, CTLA4 and TIGIT Expression on T and NK Cells in Granulomatous Diseases: Sarcoidosis and ANCA-Associated Vasculitis
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells
por: Chambers, Andrea M., et al.
Publicado: (2018)

Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia
por: Yao, Danlin, et al.
Publicado: (2020)

Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT
por: Charpak-Amikam, Yoav, et al.
Publicado: (2022)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

P811: PIM2 KINASE REGULATES TIGIT EXPRESSION AND ENERGY METABOLISM IN NK CELLS OF PATIENTS WITH MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
por: Tsakmaklis, Anastasia, et al.
Publicado: (2023)

Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia
por: Valhondo, Isabel, et al.
Publicado: (2020)

Analysis of the Characteristics of TIGIT-Expressing CD3(−)CD56(+)NK Cells in Controlling Different Stages of HIV-1 Infection
por: Zhang, Xin, et al.
Publicado: (2021)

Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
por: Wang, Jiao, et al.
Publicado: (2018)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals
por: Yin, Xiaowan, et al.
Publicado: (2018)

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8(+) T Cells
por: Zhou, Xiu-Man, et al.
Publicado: (2018)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy
por: Ducoin, Kathleen, et al.
Publicado: (2022)

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
por: Judge, Sean J, et al.
Publicado: (2020)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

TIGIT in Lung Cancer: Potential Theranostic Implications
por: Pescia, Carlo, et al.
Publicado: (2023)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells
por: González-Ochoa, S., et al.
Publicado: (2022)

Increased expression of TIGIT and KLRG1 correlates with impaired CD56(bright) NK cell immunity in HPV16-related cervical intraepithelial neoplasia
por: Nie, You, et al.
Publicado: (2022)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t3tm65i4uein6pq662te476e9h